Mumbai: Pharma major Lupin announced today the successful completion of an inspection carried out by the US FDA at its Nagpur facility. The inspection concluded without any observations. Lupin’s Nagpur facility is the company’s latest facility and manufactures oral solid products.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Paediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 11^th and 7^th largest generics pharmaceutical company by market capitalization (December 31^st, 2017, Bloomberg) and revenues (September 30^th, 2017, Bloomberg LTM) respectively. The Company is the 4^th largest pharmaceutical player in the US by prescriptions (IQVIA MAT December 2017); 2^nd largest Indian pharmaceutical company by global revenues (September 30^th, 2017, Bloomberg LTM); 6^th largest generic pharmaceutical player in Japan and 5^th largest company in Indian Pharmaceutical Market (IQVIA MAT December2017).

For the financial year ended 31^st March, 2017, Lupin’s consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com  for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal  CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Or

Arvind Bothra
Head – Investor Relations
Email: arvindbothra@lupin.com
Ph: +91-22-66402137

*Safe Harbor Statement